STOCK TITAN

[Form 4] Collegium Pharmaceutical, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Rubric Capital Management LP and David Rosen reported the sale of 25,000 shares of Collegium Pharmaceutical, Inc. (COLL) on 08/13/2025 at a weighted average price of $37.85 per share, with transaction prices ranging from $37.71 to $38.10. After the sale, the Reporting Persons collectively beneficially own 3,132,743 shares indirectly through funds/accounts managed by Rubric Capital.

The Form 4 clarifies Rubric Capital is the investment adviser to the reporting vehicles and Mr. Rosen is the managing member of the general partner; the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The Reporting Persons offer to provide detailed per-price sale breakdowns to the issuer or SEC staff upon request.

Rubric Capital Management LP e David Rosen hanno dichiarato la vendita di 25.000 azioni di Collegium Pharmaceutical, Inc. (COLL) il 13/08/2025 a un prezzo medio ponderato di $37,85 per azione, con prezzi di transazione compresi tra $37,71 e $38,10. Dopo la vendita, le Persone Segnalanti detengono collettivamente in modo benefico 3.132.743 azioni indirettamente tramite fondi/conti gestiti da Rubric Capital.

Il Modulo 4 precisa che Rubric Capital è il consulente di investimento dei veicoli segnalanti e che il Sig. Rosen è il membro dirigente del general partner; la dichiarazione rinuncia alla titolarità beneficiaria salvo per qualsiasi interesse pecuniario. Le Persone Segnalanti si rendono disponibili a fornire all'emittente o al personale della SEC, su richiesta, un dettaglio delle vendite per singolo prezzo.

Rubric Capital Management LP y David Rosen informaron la venta de 25.000 acciones de Collegium Pharmaceutical, Inc. (COLL) el 13/08/2025 a un precio medio ponderado de $37,85 por acción, con precios de transacción entre $37,71 y $38,10. Tras la venta, las Personas Informantes poseen colectivamente de forma beneficiaria 3.132.743 acciones de manera indirecta a través de fondos/cuentas gestionados por Rubric Capital.

El Formulario 4 aclara que Rubric Capital es el asesor de inversión de los vehículos informantes y que el Sr. Rosen es el miembro gerente del general partner; la presentación renuncia a la propiedad beneficiaria salvo en la medida de cualquier interés pecuniario. Las Personas Informantes ofrecen proporcionar desgloses detallados de las ventas por precio al emisor o al personal de la SEC si se lo solicitan.

Rubric Capital Management LP와 David Rosen은 2025년 8월 13일 Collegium Pharmaceutical, Inc.(COLL) 주식 25,000주를 주당 가중평균 $37.85에 매도했다고 보고했습니다. 거래 가격 범위는 $37.71에서 $38.10였습니다. 매도 후 보고자들은 Rubric Capital이 운용하는 펀드/계정을 통해 간접적으로 총 3,132,743주를 집합적으로 실질 보유하고 있습니다.

Form 4는 Rubric Capital이 보고 대상 투자기구들의 투자자문사이며 Rosen 씨는 제너럴 파트너의 매니징 멤버임을 명시하고 있습니다. 제출서는 금전적 이익 범위를 제외한 실질적 소유권을 부인합니다. 보고자들은 발행사나 SEC 직원의 요청이 있을 경우 가격별 매도 내역을 상세히 제공하겠다고 밝혔습니다.

Rubric Capital Management LP et David Rosen ont déclaré la vente de 25 000 actions de Collegium Pharmaceutical, Inc. (COLL) le 13/08/2025 à un prix moyen pondéré de 37,85 $ par action, les prix de transaction variant de 37,71 $ à 38,10 $. Après la vente, les personnes déclarantes détiennent collectivement à titre bénéficiaire 3 132 743 actions de façon indirecte via des fonds/comptes gérés par Rubric Capital.

Le formulaire 4 précise que Rubric Capital est le conseiller en investissement des véhicules déclarants et que M. Rosen est le membre dirigeant du general partner ; le dépôt décline la propriété bénéficiaire sauf dans la mesure d'un intérêt pécuniaire. Les personnes déclarantes se proposent de fournir à l'émetteur ou au personnel de la SEC, sur demande, le détail des ventes par prix.

Rubric Capital Management LP und David Rosen meldeten am 13.08.2025 den Verkauf von 25.000 Aktien der Collegium Pharmaceutical, Inc. (COLL) zu einem gewichteten Durchschnittspreis von $37,85 pro Aktie; die Transaktionspreise lagen zwischen $37,71 und $38,10. Nach dem Verkauf halten die meldepflichtigen Personen gemeinschaftlich wirtschaftlich 3.132.743 Aktien indirekt über von Rubric Capital verwaltete Fonds/Konten.

Das Formular 4 stellt klar, dass Rubric Capital Investment Adviser der meldepflichtigen Vehikel ist und Herr Rosen geschäftsführendes Mitglied des General Partners ist; die Einreichung schließt wirtschaftliches Eigentum außer im Umfang etwaiger pecuniärer Interessen aus. Die Melder bieten an, dem Emittenten oder dem SEC-Personal auf Anfrage eine detaillierte Aufschlüsselung der Verkäufe nach Preis zur Verfügung zu stellen.

Positive
  • Complete and transparent disclosure of the sale including weighted average price and price range
  • Large remaining indirect stake of 3,132,743 shares indicates continued substantial ownership
Negative
  • Insider-affiliated sale of 25,000 shares on 08/13/2025, which may be viewed negatively by some investors

Insights

TL;DR: Director-affiliated adviser sold a small portion of a large indirect stake; overall ownership remains substantial and disclosure is complete.

The 25,000-share disposition represents a modest reduction relative to the 3.13 million shares reported as beneficially owned, suggesting the sale is not a material change to ownership structure. The filing is properly executed by both Rubric Capital and David Rosen and includes the weighted average price and price range, which supports transparency for investors and regulators. The offer to provide per-price details on request aligns with best practices for disclosure. No derivatives or additional transactions are reported.

TL;DR: Transaction disclosed correctly under Section 16; maintains regulatory compliance while signaling routine portfolio activity.

The Form 4 attributes the shares to Rubric Vehicles with indirect ownership through the adviser and general partner structure, and includes the customary disclaimer of beneficial ownership limits. The sale was executed in multiple tranches across a narrow price band, which is documented as a weighted average. From a governance perspective, the dual signatures and explicit explanation reduce ambiguity about control and reporting responsibility. The filing contains no indication of policy-driven plan sales or derivates activity.

Rubric Capital Management LP e David Rosen hanno dichiarato la vendita di 25.000 azioni di Collegium Pharmaceutical, Inc. (COLL) il 13/08/2025 a un prezzo medio ponderato di $37,85 per azione, con prezzi di transazione compresi tra $37,71 e $38,10. Dopo la vendita, le Persone Segnalanti detengono collettivamente in modo benefico 3.132.743 azioni indirettamente tramite fondi/conti gestiti da Rubric Capital.

Il Modulo 4 precisa che Rubric Capital è il consulente di investimento dei veicoli segnalanti e che il Sig. Rosen è il membro dirigente del general partner; la dichiarazione rinuncia alla titolarità beneficiaria salvo per qualsiasi interesse pecuniario. Le Persone Segnalanti si rendono disponibili a fornire all'emittente o al personale della SEC, su richiesta, un dettaglio delle vendite per singolo prezzo.

Rubric Capital Management LP y David Rosen informaron la venta de 25.000 acciones de Collegium Pharmaceutical, Inc. (COLL) el 13/08/2025 a un precio medio ponderado de $37,85 por acción, con precios de transacción entre $37,71 y $38,10. Tras la venta, las Personas Informantes poseen colectivamente de forma beneficiaria 3.132.743 acciones de manera indirecta a través de fondos/cuentas gestionados por Rubric Capital.

El Formulario 4 aclara que Rubric Capital es el asesor de inversión de los vehículos informantes y que el Sr. Rosen es el miembro gerente del general partner; la presentación renuncia a la propiedad beneficiaria salvo en la medida de cualquier interés pecuniario. Las Personas Informantes ofrecen proporcionar desgloses detallados de las ventas por precio al emisor o al personal de la SEC si se lo solicitan.

Rubric Capital Management LP와 David Rosen은 2025년 8월 13일 Collegium Pharmaceutical, Inc.(COLL) 주식 25,000주를 주당 가중평균 $37.85에 매도했다고 보고했습니다. 거래 가격 범위는 $37.71에서 $38.10였습니다. 매도 후 보고자들은 Rubric Capital이 운용하는 펀드/계정을 통해 간접적으로 총 3,132,743주를 집합적으로 실질 보유하고 있습니다.

Form 4는 Rubric Capital이 보고 대상 투자기구들의 투자자문사이며 Rosen 씨는 제너럴 파트너의 매니징 멤버임을 명시하고 있습니다. 제출서는 금전적 이익 범위를 제외한 실질적 소유권을 부인합니다. 보고자들은 발행사나 SEC 직원의 요청이 있을 경우 가격별 매도 내역을 상세히 제공하겠다고 밝혔습니다.

Rubric Capital Management LP et David Rosen ont déclaré la vente de 25 000 actions de Collegium Pharmaceutical, Inc. (COLL) le 13/08/2025 à un prix moyen pondéré de 37,85 $ par action, les prix de transaction variant de 37,71 $ à 38,10 $. Après la vente, les personnes déclarantes détiennent collectivement à titre bénéficiaire 3 132 743 actions de façon indirecte via des fonds/comptes gérés par Rubric Capital.

Le formulaire 4 précise que Rubric Capital est le conseiller en investissement des véhicules déclarants et que M. Rosen est le membre dirigeant du general partner ; le dépôt décline la propriété bénéficiaire sauf dans la mesure d'un intérêt pécuniaire. Les personnes déclarantes se proposent de fournir à l'émetteur ou au personnel de la SEC, sur demande, le détail des ventes par prix.

Rubric Capital Management LP und David Rosen meldeten am 13.08.2025 den Verkauf von 25.000 Aktien der Collegium Pharmaceutical, Inc. (COLL) zu einem gewichteten Durchschnittspreis von $37,85 pro Aktie; die Transaktionspreise lagen zwischen $37,71 und $38,10. Nach dem Verkauf halten die meldepflichtigen Personen gemeinschaftlich wirtschaftlich 3.132.743 Aktien indirekt über von Rubric Capital verwaltete Fonds/Konten.

Das Formular 4 stellt klar, dass Rubric Capital Investment Adviser der meldepflichtigen Vehikel ist und Herr Rosen geschäftsführendes Mitglied des General Partners ist; die Einreichung schließt wirtschaftliches Eigentum außer im Umfang etwaiger pecuniärer Interessen aus. Die Melder bieten an, dem Emittenten oder dem SEC-Personal auf Anfrage eine detaillierte Aufschlüsselung der Verkäufe nach Preis zur Verfügung zu stellen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubric Capital Management LP

(Last) (First) (Middle)
155 EAST 44TH ST, SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share 08/13/2025 S 25,000 D $37.85(3) 3,132,743 I See footnotes(1)(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Rubric Capital Management LP

(Last) (First) (Middle)
155 EAST 44TH ST, SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Rosen David Efraim

(Last) (First) (Middle)
155 EAST 44TH ST., SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital.
2. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.71 to $38.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Rubric Capital Management LP, By: /s/ Michael Nachmani, its Chief Operating Officer 08/15/2025
/s/ David Rosen 08/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for COLL disclose?

The filing discloses a sale of 25,000 shares on 08/13/2025 at a weighted average price of $37.85, with prices ranging $37.71–$38.10.

Who filed the Form 4 for COLL and what is their relationship to the company?

The Form 4 was filed by Rubric Capital Management LP and David Rosen; Rubric is the investment adviser to the reported funds and Mr. Rosen is the managing member of the general partner.

How many COLL shares are beneficially owned after the reported transaction?

After the sale, the Reporting Persons beneficially own 3,132,743 shares indirectly through the Rubric Vehicles.

Were any derivative transactions reported in this filing for COLL?

No. Table II shows no derivative securities acquired, disposed of, or beneficially owned in this filing.

Is the price in the Form 4 a single trade price?

No. The price of $37.85 is a weighted average; the shares were sold in multiple transactions at prices from $37.71 to $38.10.
Collegium Pharmaceutical Inc

NASDAQ:COLL

COLL Rankings

COLL Latest News

COLL Latest SEC Filings

COLL Stock Data

1.19B
30.93M
1.69%
117.04%
13.09%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
STOUGHTON